Contrary to expectations, adding Tafasitamab and Lenalidomide to the R-CHOP regimen for diffuse large B-cell lymphoma resulted in only a marginal increase in toxicity. The rate of high-grade febrile neutropenia was only 3-4% higher, a pleasant surprise compared to previous combination trials.
Position clinical trials not as experiments, but as a way for patients to receive tomorrow's standard-of-care treatments years ahead of FDA approval. This reframe is a powerful communication tool for patient recruitment, especially in fields like lymphoma where trial success rates are high.
In relapsed/refractory mantle cell lymphoma, the bispecific antibody glofitimab is achieving complete remission rates above 75%. This is unprecedented and notably better than existing CAR-T therapy data, suggesting an accessible, off-the-shelf immunotherapy can outperform more complex cellular therapies in this setting.
The tolerability of therapies like bispecific antibodies has significantly improved not from changing the drug, but from evolving supportive care. Implementing low-threshold protocols for interventions like tocilizumab (for CRS) and IVIG (for infections) has made these once-complex treatments much safer and more manageable.
A critical but often overlooked step in managing high-risk tumor lysis syndrome (TLS) is checking for G6PD deficiency before administering Rasburicase. This is crucial for patient safety, especially in populations with a higher prevalence of the deficiency, such as those of Mediterranean descent.
The next frontier in cellular therapy is in-vivo CAR-T, where a gene for the CAR receptor is delivered into the patient (e.g., via mRNA lipid nanoparticles) to create CAR-T cells internally. This eliminates the complex and costly external manufacturing process, potentially creating an 'off-the-shelf' CAR-T therapy.